Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
暂无分享,去创建一个
Jack T Stapleton | Arunachalam Ilancheran | Frank Struyf | Jorge Salmerón | Archana Chatterjee | Marie-Pierre David | Gary Dubin | Eduardo Lazcano-Ponce | H. Kitchener | S. Garland | R. Verheijen | M. Levin | M. Cruickshank | E. Lazcano-Ponce | J. Salmerón | Wim Quint | F. Struyf | G. Dubin | D. Money | A. Ilancheran | J. Stapleton | B. Geeraerts | A. Szarewski | B. Romanowski | D. Descamps | C. Bouchard | M. David | M. Martens | S Rachel Skinner | Suzanne M Garland | Karin Hardt | A. Chatterjee | Margaret E Cruickshank | Dominique Descamps | Henry Kitchener | Brecht Geeraerts | Barbara Romanowski | Anne Szarewski | M Rowena Del Rosario-Raymundo | René H M Verheijen | Swee Chong Quek | Daniel P da Silva | Kah Leng Fong | Céline Bouchard | Deborah M Money | Myron J Levin | Mark Martens | Wim Quint | Dorothée Meric | S. R. Skinner | S. C. Quek | Dorothée Meric | K. Hardt | K. L. Fong | M. R. D. Rosario-Raymundo | S. R. Skinner | W. Quint | Suzanne M. Garland | Myron J. Levin | Jack T Stapleton | Deborah M Money | Swee Chong Quek | Margaret E Cruickshank | René H.M. Verheijen | Daniel Da Silva | A. Ilancheran
[1] D. Hendrick,et al. Introduction , 1998, Thorax.
[2] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[3] David R. Scott,et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA‐positive, cytologically negative women , 2002, Cancer.
[4] N. Muñoz,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.
[5] Susun Bellew,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2010 .
[6] N. Muñoz,et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.
[7] G. Zimet,et al. Literature review of human papillomavirus vaccine acceptability among women over 26 years. , 2009, Vaccine.
[8] K. Syrjänen. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. , 2011, European journal of gynaecological oncology.
[9] C. Wheeler,et al. Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .
[10] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.
[11] P. Castle,et al. HPV vaccination: for women of all ages? , 2014, The Lancet.
[12] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[13] H. Trottier,et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. , 2010, Cancer research.
[14] Masha Fridman,et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study , 2011, The Lancet.
[15] End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.
[16] N. Kiviat,et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[17] A. Muñoz,et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.
[18] S. Pagliusi,et al. Efficacy and other milestones for human papillomavirus vaccine introduction. , 2004, Vaccine.
[19] P. Naud,et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine , 2014, Human vaccines & immunotherapeutics.
[20] S. Garland,et al. Clinical update , 2022 .
[21] B. Spiessens,et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials , 2009, Human vaccines.
[22] D. Lowy,et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.
[23] Edson Duarte Moreira Júnior,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.
[24] C. Wheeler,et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 , 2012, International journal of cancer.
[25] J. Cuzick,et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.
[26] L. Pinto,et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine , 2008, Human vaccines.
[27] Daron G Ferris,et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.
[28] J Dillner,et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland , 2007, British Journal of Cancer.
[29] A. Kaufmann,et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study , 2014, BJOG : an international journal of obstetrics and gynaecology.
[30] M. Sherman,et al. Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection , 2004, Cancer Epidemiology Biomarkers & Prevention.
[31] C J L M Meijer,et al. The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.
[32] C. Wheeler,et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[33] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.
[34] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[35] D. Lowy,et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. , 2011, Vaccine.
[36] L. Bruni,et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.
[37] B Romanowski,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.
[38] H. Chesson,et al. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. , 2011, Vaccine.
[39] Joakim Dillner,et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.
[40] W. Quint,et al. A Human Papilloma Virus Testing Algorithm Comprising a Combination of the L1 Broad-Spectrum SPF10 PCR Assay and a Novel E6 High-Risk Multiplex Type-Specific Genotyping PCR Assay , 2013, Journal of Clinical Microbiology.
[41] Diane Solomon,et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. , 2011, Cancer discovery.
[42] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[43] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[44] F. Bray,et al. Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries , 2005, Cancer Epidemiology Biomarkers & Prevention.
[45] Sue J Goldie,et al. Health and economic implications of HPV vaccination in the United States. , 2008, The New England journal of medicine.
[46] W. Quint,et al. Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.
[47] C. Wheeler,et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[48] D. Lowy,et al. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. , 2015, The Lancet. Oncology.
[49] C. Wheeler,et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection , 2009, Human vaccines.
[50] S. Wacholder,et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. , 2014, Vaccine.
[51] S. Wacholder,et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. , 2010, Journal of the National Cancer Institute.
[52] C. Wheeler,et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years , 2009, The Lancet.
[53] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[54] N. Kiviat,et al. Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. , 2010, The Journal of infectious diseases.
[55] S. Wacholder,et al. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. , 2013, American journal of epidemiology.
[56] C. Wheeler,et al. Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.